Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP

Wan-Jung Lu, Nen Chung Chang, Thanasekaran Jayakumar, Jiun Cheng Liao, Mei Jiun Lin, Shwu Huey Wang, Duen Suey Chou, Philip Aloysius Thomas, Joen Rong Sheu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction CME-1, a novel water-soluble polysaccharide, was purified from the mycelia of Cordyceps sinensis, and its chemical structure was characterized to contain mannose and galactose in a ratio of 4:6 (27.6 kDa). CME-1 was originally observed to exert a potent inhibitory effect on tumor migration and a cytoprotective effect against oxidative stress. Activation of platelets caused by arterial thrombosis is relevant to various cardiovascular diseases (CVDs). However, no data are available concerning the effects of CME-1 on platelet activation. Hence, the purpose of this study was to examine the ex vivo and in vivo antithrombotic effects of CME-1 and its possible mechanisms in platelet activation.

Methods The aggregometry, immunoblotting, flow cytometric analysis and platelet functional analysis were used in this study.

Results CME-1 (2.3-7.6 μM) exhibited highly potent activity in inhibiting human platelet aggregation when stimulated by collagen, thrombin, and arachidonic acid but not by U46619. CME-1 inhibited platelet activation accompanied by inhibiting Akt, mitogen-activated protein kinases (MAPKs), thromboxane B2 (TxB2) and hydroxyl radical (OH) formation. However, CME-1 interrupted neither FITC-triflavin nor FITC-collagen binding to platelets. CME-1 markedly increased cyclic AMP levels, but not cyclic GMP levels, and stimulated vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, but not ODQ, an inhibitor of guanylate cyclase, obviously reversed the CME-1-mediated effects on platelet aggregation and vasodilator-stimulated phosphoprotein (VASP), Akt, p38 MAPK phosphorylation, and TxB2 formation. CME-1 substantially prolonged the closure time of whole blood and the occlusion time of platelet plug formation.

Conclusion This study demonstrates for the first time that CME-1 exhibits highly potent antiplatelet activity that may initially activate adenylate cyclase/cyclic AMP and, subsequently, inhibit intracellular signals (such as Akt and MAPKs), ultimately inhibiting platelet activation. This novel role of CME-1 indicates that CME-1 exhibits high potential for application in treating and preventing CVDs.

Original languageEnglish
Pages (from-to)1301-1310
Number of pages10
JournalThrombosis Research
Volume134
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Cordyceps
Mycelium
Platelet Activation
Adenylyl Cyclases
Cyclic AMP
Polysaccharides
Thromboxane B2
Blood Platelets
Fluorescein-5-isothiocyanate
Mitogen-Activated Protein Kinases
Platelet Aggregation
Cardiovascular Diseases
Collagen
Phosphorylation
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Guanylate Cyclase
Cyclic GMP
p38 Mitogen-Activated Protein Kinases
Mannose
Galactose

Keywords

  • CME-1
  • Cordyceps sinensis
  • Cyclic AMP
  • Platelet activation
  • Polysaccharide

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP. / Lu, Wan-Jung; Chang, Nen Chung; Jayakumar, Thanasekaran; Liao, Jiun Cheng; Lin, Mei Jiun; Wang, Shwu Huey; Chou, Duen Suey; Thomas, Philip Aloysius; Sheu, Joen Rong.

In: Thrombosis Research, Vol. 134, No. 6, 01.12.2014, p. 1301-1310.

Research output: Contribution to journalArticle

@article{37b8c8e9cf6e4b37af1ddd079eba0197,
title = "Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP",
abstract = "Introduction CME-1, a novel water-soluble polysaccharide, was purified from the mycelia of Cordyceps sinensis, and its chemical structure was characterized to contain mannose and galactose in a ratio of 4:6 (27.6 kDa). CME-1 was originally observed to exert a potent inhibitory effect on tumor migration and a cytoprotective effect against oxidative stress. Activation of platelets caused by arterial thrombosis is relevant to various cardiovascular diseases (CVDs). However, no data are available concerning the effects of CME-1 on platelet activation. Hence, the purpose of this study was to examine the ex vivo and in vivo antithrombotic effects of CME-1 and its possible mechanisms in platelet activation.Methods The aggregometry, immunoblotting, flow cytometric analysis and platelet functional analysis were used in this study.Results CME-1 (2.3-7.6 μM) exhibited highly potent activity in inhibiting human platelet aggregation when stimulated by collagen, thrombin, and arachidonic acid but not by U46619. CME-1 inhibited platelet activation accompanied by inhibiting Akt, mitogen-activated protein kinases (MAPKs), thromboxane B2 (TxB2) and hydroxyl radical (OH•) formation. However, CME-1 interrupted neither FITC-triflavin nor FITC-collagen binding to platelets. CME-1 markedly increased cyclic AMP levels, but not cyclic GMP levels, and stimulated vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, but not ODQ, an inhibitor of guanylate cyclase, obviously reversed the CME-1-mediated effects on platelet aggregation and vasodilator-stimulated phosphoprotein (VASP), Akt, p38 MAPK phosphorylation, and TxB2 formation. CME-1 substantially prolonged the closure time of whole blood and the occlusion time of platelet plug formation.Conclusion This study demonstrates for the first time that CME-1 exhibits highly potent antiplatelet activity that may initially activate adenylate cyclase/cyclic AMP and, subsequently, inhibit intracellular signals (such as Akt and MAPKs), ultimately inhibiting platelet activation. This novel role of CME-1 indicates that CME-1 exhibits high potential for application in treating and preventing CVDs.",
keywords = "CME-1, Cordyceps sinensis, Cyclic AMP, Platelet activation, Polysaccharide",
author = "Wan-Jung Lu and Chang, {Nen Chung} and Thanasekaran Jayakumar and Liao, {Jiun Cheng} and Lin, {Mei Jiun} and Wang, {Shwu Huey} and Chou, {Duen Suey} and Thomas, {Philip Aloysius} and Sheu, {Joen Rong}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.thromres.2014.09.023",
language = "English",
volume = "134",
pages = "1301--1310",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP

AU - Lu, Wan-Jung

AU - Chang, Nen Chung

AU - Jayakumar, Thanasekaran

AU - Liao, Jiun Cheng

AU - Lin, Mei Jiun

AU - Wang, Shwu Huey

AU - Chou, Duen Suey

AU - Thomas, Philip Aloysius

AU - Sheu, Joen Rong

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Introduction CME-1, a novel water-soluble polysaccharide, was purified from the mycelia of Cordyceps sinensis, and its chemical structure was characterized to contain mannose and galactose in a ratio of 4:6 (27.6 kDa). CME-1 was originally observed to exert a potent inhibitory effect on tumor migration and a cytoprotective effect against oxidative stress. Activation of platelets caused by arterial thrombosis is relevant to various cardiovascular diseases (CVDs). However, no data are available concerning the effects of CME-1 on platelet activation. Hence, the purpose of this study was to examine the ex vivo and in vivo antithrombotic effects of CME-1 and its possible mechanisms in platelet activation.Methods The aggregometry, immunoblotting, flow cytometric analysis and platelet functional analysis were used in this study.Results CME-1 (2.3-7.6 μM) exhibited highly potent activity in inhibiting human platelet aggregation when stimulated by collagen, thrombin, and arachidonic acid but not by U46619. CME-1 inhibited platelet activation accompanied by inhibiting Akt, mitogen-activated protein kinases (MAPKs), thromboxane B2 (TxB2) and hydroxyl radical (OH•) formation. However, CME-1 interrupted neither FITC-triflavin nor FITC-collagen binding to platelets. CME-1 markedly increased cyclic AMP levels, but not cyclic GMP levels, and stimulated vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, but not ODQ, an inhibitor of guanylate cyclase, obviously reversed the CME-1-mediated effects on platelet aggregation and vasodilator-stimulated phosphoprotein (VASP), Akt, p38 MAPK phosphorylation, and TxB2 formation. CME-1 substantially prolonged the closure time of whole blood and the occlusion time of platelet plug formation.Conclusion This study demonstrates for the first time that CME-1 exhibits highly potent antiplatelet activity that may initially activate adenylate cyclase/cyclic AMP and, subsequently, inhibit intracellular signals (such as Akt and MAPKs), ultimately inhibiting platelet activation. This novel role of CME-1 indicates that CME-1 exhibits high potential for application in treating and preventing CVDs.

AB - Introduction CME-1, a novel water-soluble polysaccharide, was purified from the mycelia of Cordyceps sinensis, and its chemical structure was characterized to contain mannose and galactose in a ratio of 4:6 (27.6 kDa). CME-1 was originally observed to exert a potent inhibitory effect on tumor migration and a cytoprotective effect against oxidative stress. Activation of platelets caused by arterial thrombosis is relevant to various cardiovascular diseases (CVDs). However, no data are available concerning the effects of CME-1 on platelet activation. Hence, the purpose of this study was to examine the ex vivo and in vivo antithrombotic effects of CME-1 and its possible mechanisms in platelet activation.Methods The aggregometry, immunoblotting, flow cytometric analysis and platelet functional analysis were used in this study.Results CME-1 (2.3-7.6 μM) exhibited highly potent activity in inhibiting human platelet aggregation when stimulated by collagen, thrombin, and arachidonic acid but not by U46619. CME-1 inhibited platelet activation accompanied by inhibiting Akt, mitogen-activated protein kinases (MAPKs), thromboxane B2 (TxB2) and hydroxyl radical (OH•) formation. However, CME-1 interrupted neither FITC-triflavin nor FITC-collagen binding to platelets. CME-1 markedly increased cyclic AMP levels, but not cyclic GMP levels, and stimulated vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, but not ODQ, an inhibitor of guanylate cyclase, obviously reversed the CME-1-mediated effects on platelet aggregation and vasodilator-stimulated phosphoprotein (VASP), Akt, p38 MAPK phosphorylation, and TxB2 formation. CME-1 substantially prolonged the closure time of whole blood and the occlusion time of platelet plug formation.Conclusion This study demonstrates for the first time that CME-1 exhibits highly potent antiplatelet activity that may initially activate adenylate cyclase/cyclic AMP and, subsequently, inhibit intracellular signals (such as Akt and MAPKs), ultimately inhibiting platelet activation. This novel role of CME-1 indicates that CME-1 exhibits high potential for application in treating and preventing CVDs.

KW - CME-1

KW - Cordyceps sinensis

KW - Cyclic AMP

KW - Platelet activation

KW - Polysaccharide

UR - http://www.scopus.com/inward/record.url?scp=84916207120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916207120&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2014.09.023

DO - 10.1016/j.thromres.2014.09.023

M3 - Article

VL - 134

SP - 1301

EP - 1310

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -